Rentokil Initial PLC
RTO: XLON (GBR)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| LOCK|g? | LOCK|k%K> | LOCK|Q?bx&$% |
Rentokil: Trading Update Indicates North America Sales Recovery on Track
Wide-moat Rentokil recorded fourth-quarter organic revenue growth in North America of 1.5%, which aligns broadly with its previous full-year guidance of 1%. At the group level, organic revenue growth was 3% for the period. We continue to anticipate a normalization in the organic performance of the US business from 2025 on, as recent sales and marketing and employee benefit investments bear fruit. We make no changes to our GBX 620 fair value estimate and view the shares as materially undervalued.
